Abstract

Unannounced to prescribers or patients, Novo Nordisk have changed the manufacturing process of their human insulins from enzymatic modification of pig insulin (emp) to direct biosynthesis of genetically engineered yeast cells (pyr). The preservative for Human Actrapid insulin has also been changed from phenol to meta-cresol. No warning of this change was sent to pharmacists, doctors, diabetes specialists or patients.